Cooperative Agreement R01CA171767

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

Award Summary The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a Project Grant of $396,799 to the University of Pittsburgh effective April 1, 2026, through March 31, 2028. This research initiative focuses on developing biomarkers and computational models to predict adenoma recurrence in patients with advanced adenomas (AA), a critical precursor to colorectal cancer. The project employs two novel approaches: evaluation of...

Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of therapy resistance and tumor regeneration in locally advanced rectal cancer (LARC). The project, initiated April 1, 2026, and extending through March 31, 2031, will deliver research products including genomic and transcriptomic analyses of pre-treatment LARC tumors, mechanistic studies utilizing...

Federal Cooperative Agreement Summary The Beckman Research Institute of the City of Hope received a $738,675 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded March 16, 2026, with completion targeted for February 28, 2031. The Institute will develop an innovative exosome-based liquid biopsy assay designed to enable non-invasive early detection of colorectal adenomas and cancers from a single blood draw....

Grant Summary The University of Chicago received a $421,685 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for research activities extending from July 1, 2026 through June 30, 2028. The award supports investigation into targeting TET3 cytosine demethylase to enhance immunogenic radiosensitization in colorectal cancer, with a focus on mismatch repair-proficient (pMMR) tumors that currently demonstrate resistance to immune...

Summary The University of Southern California received a $426,828 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for research spanning August 15, 2025 through July 31, 2027. The funded research focuses on developing DNA methylation (DNAM) markers to enable early detection and monitoring of tumor burden in bladder cancer patients. The project addresses a critical clinical need by establishing non-invasive biomarkers...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...

Grant Award Summary Cold Spring Harbor Laboratory received a $704,182 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on June 16, 2026, with completion targeted for May 31, 2031. The grant funds fundamental research to elucidate the non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer (CRC). The research utilizes an innovative mouse model that replicates the stepwise acquisition of...

Federal Grant Award Summary Health Research, Inc. (Roswell Park Division), operating as Health Research At Roswell Park in Buffalo, New York, received a $446,112 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2026, through August 31, 2028. The award funds research to develop enhanced targeted therapies for colorectal cancer (CRC), specifically investigating the synergistic potential of combining...

GRANT SUMMARY The National Cancer Institute awarded Weill Medical College of Cornell University a $607,849 Project Grant on August 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a five-year research initiative examining mechanisms of genetic and non-genetic resistance to KRAS (Kirsten Rat Sarcoma) inhibition in lung adenocarcinoma and colorectal cancer. The research aims to identify why patients develop resistance to newly emerged mutant-selective and pan-KRAS...